share_log

Morgan Stanley Maintains Equal-Weight on Genmab, Maintains $31 Price Target

Benzinga ·  Sep 11 23:36  · Ratings

Morgan Stanley analyst Vikram Purohit maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and maintains $31 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment